PMID- 15477868
OWN - NLM
STAT- MEDLINE
DCOM- 20041207
LR  - 20220309
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 91
IP  - 9
DP  - 2004 Nov 1
TI  - Inverse relationship between ER-beta and SRC-1 predicts outcome in 
      endocrine-resistant breast cancer.
PG  - 1687-93
AB  - The oestrogen receptor (ER) interacts with coactivator proteins to modulate genes 
      central to breast tumour progression. Oestrogen receptor is encoded for by two 
      genes, ER-alpha and ER-beta. Although ER-alpha has been well characterized, the 
      role of ER-beta as a prognostic indicator remains unresolved. To determine 
      isoform-specific expression of ER and coexpression with activator proteins, we 
      examined the expression and localisation of ER-alpha, ER-beta and the coactivator 
      protein steroid receptor coactivator 1 (SRC-1) by immunohistochemistry and 
      immunofluorescence in a cohort of human breast cancer patients (n=150). Relative 
      levels of SRC-1 in primary breast cultures derived from patient tumours in the 
      presence of beta-oestradiol and tamoxifen was assessed using Western blotting 
      (n=14). Oestrogen receptor-beta protein expression was associated with 
      disease-free survival (DFS) and inversely associated with the expression of HER2 
      (P=0.0008 and P<0.0001, respectively), whereas SRC-1 was negatively associated 
      with DFS and positively correlated with HER2 (P<0.0001 and P<0.0001, 
      respectively). Steroid receptor coactivator 1 protein expression was regulated in 
      response to beta-oestradiol or tamoxifen in 57% of the primary tumour cell 
      cultures. Protein expression of ER-beta and SRC-1 was inversely associated 
      (P=0.0001). The association of ER-beta protein expression with increased DFS and 
      its inverse relationship with SRC-1 suggests a role for these proteins in 
      predicting outcome in breast cancer.
FAU - Myers, E
AU  - Myers E
AD  - Department of Surgery, Saint Vincent's University Hospital, Dublin 4, Ireland.
FAU - Fleming, F J
AU  - Fleming FJ
FAU - Crotty, T B
AU  - Crotty TB
FAU - Kelly, G
AU  - Kelly G
FAU - McDermott, E W
AU  - McDermott EW
FAU - O'higgins, N J
AU  - O'higgins NJ
FAU - Hill, A D K
AU  - Hill AD
FAU - Young, L S
AU  - Young LS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Transcription Factors)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 2.3.1.48 (Histone Acetyltransferases)
RN  - EC 2.3.1.48 (NCOA1 protein, human)
RN  - EC 2.3.1.48 (Nuclear Receptor Coactivator 1)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Hormonal/pharmacology
MH  - Blotting, Western
MH  - Breast Neoplasms/drug therapy/*metabolism/pathology
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Estradiol/pharmacology
MH  - Estrogen Receptor alpha/*metabolism
MH  - Estrogen Receptor beta/*metabolism
MH  - Female
MH  - Fluorescent Antibody Technique
MH  - Histone Acetyltransferases
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Middle Aged
MH  - Neoplasms, Hormone-Dependent/drug therapy/*metabolism/pathology
MH  - Nuclear Receptor Coactivator 1
MH  - Receptor, ErbB-2/metabolism
MH  - Survival Rate
MH  - Tamoxifen/pharmacology
MH  - Transcription Factors/*metabolism
MH  - Treatment Outcome
PMC - PMC2409954
EDAT- 2004/10/13 09:00
MHDA- 2004/12/16 09:00
PMCR- 2005/10/12
CRDT- 2004/10/13 09:00
PHST- 2004/10/13 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/13 09:00 [entrez]
PHST- 2005/10/12 00:00 [pmc-release]
AID - 6602156 [pii]
AID - 10.1038/sj.bjc.6602156 [doi]
PST - ppublish
SO  - Br J Cancer. 2004 Nov 1;91(9):1687-93. doi: 10.1038/sj.bjc.6602156.